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A B S T R A C T
A recent publication by Levecke et al. (Int. J. Parasitol, 2018, 8, 67–69) provides important insights into the
kinetics of worm expulsion from humans following treatment with albendazole. This is an important aspect of
determining the optimal time-point for post treatment sampling to examine anthelmintic drug efficacy. The
authors conclude that for the determination of drug efficacy against Ascaris, samples should be taken not before
day 14 and recommend a period between days 14 and 21. Using this recommendation, they conclude that
previous data (Krücken et al., 2017; Int. J. Parasitol, 7, 262–271) showing a reduction of egg shedding by 75.4%
in schoolchildren in Rwanda and our conclusions from these data should be interpreted with caution. In reply to
this, we would like to indicate that the very low efficacy of 0% in one school and 52–56% in three other schools,
while the drug was fully efficient in other schools, cannot simply be explained by the time point of sampling.
Moreover, there was no correlation between the sampling day and albendazole efficacy. We would also like to
indicate that we very carefully interpreted our data and, for example, nowhere claimed that we found anthel-
mintic resistance. Rather, we stated that our data indicated that benzimidazole resistance may be suspected in
the study population. We strongly agree that the data presented by Levecke et al. suggests that recommendations
for efficacy testing of anthelmintic drugs should be revised.
A recent publication by Levecke et al. (2018) provided interesting
information on the kinetics of expulsion of Ascaris lumbricoides in hu-
mans following benzimidazole treatment. They show that expulsion of
Ascaris worms can occur as late as 10 days post treatment with 400 mg
albendazole and that this late worm expulsion affects faecal egg count
reduction (FECR= egg reduction rate, ERR), which was only 89.4% on
day 7 post treatment in their dataset but reached 100% at day 10 post
treatment. These observations add to the ongoing discussion on how to
best monitor the efficacy of anthelmintic chemotherapy.
Monitoring anthelmintic efficacy in humans currently relies solely
on faecal egg counts. Egg counts, however, suffer from several con-
founding factors such as the non-homogenous distribution of eggs in
faeces, among others (Torgerson et al., 2014; Levecke et al., 2015;
Wang et al., 2017). Novel statistical methods partially solve these issues
and account for effects of variation on confidence intervals. Still, only
few data sets are available on egg counts following treatment. Of note,
the eggCounts package (Torgerson et al., 2014; Wang et al., 2017)
developed by Reinhard Furrer's group requires such data for optimi-
zation and for informing respective Bayesian models to calculate FECRs
and their 95% confidence intervals.
The optimal timing of post-treatment sample collection depends on
various factors including host/parasite species, drug and treatment re-
gimen. For instance, in the veterinary field, Coles et al. (2006) re-
commended stool sampling 3–7 days post-treatment for levamisole,
8–10 days post-treatment for the benzimidazoles and 14–17 days post-
treatment for the macrocyclic lactones.
https://doi.org/10.1016/j.ijpddr.2018.05.004
Received 3 April 2018; Received in revised form 14 May 2018; Accepted 15 May 2018
∗ Corresponding author.
E-mail address: juergen.kruecken@fu-berlin.de (J. Krücken).
IJP: Drugs and Drug Resistance 8 (2018) 329–330
Available online 18 May 2018
2211-3207/ © 2018 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY 
license (http://creativecommons.org/licenses/BY/4.0/).
T
In a recent study among Rwandan schoolchildren (Krücken et al.,
2017), we collected FEC data on day 7–10 post treatment with alben-
dazole. We found a very high variation in the effect of treatment based
on FECR determinations between children attending different schools in
a district in southern Rwanda, and raised the suspicion that FECRs<
95% could indicate reduced efficacy, i.e. emerging benzimidazole re-
sistance. This interpretation is now criticized by Levecke and colleagues
based on their findings that a FECR of 89% on day 7 can still reach
100% on days 14 and 21 (Levecke et al. (2018)). We fully agree with
Levecke and colleagues that future study designs should take this de-
layed clearance in humans into account. We also support the conclusion
that recommendations for gathering FECR data should be revised and
that the suggestions made by Vercruysse et al. (2011) suggesting a 7–21
days interval as well as the WHO guidelines should be openly discussed
and presumably reformed. Optimally, this should involve experts from
different working groups and include also researchers interested in
other parasites shed with the faeces such as schistosomes or Giardia
duodenalis to allow the broadest and most precise collection of data
possible from such samples.
However, the large differences in FECR noted in our study (Krücken
et al., 2017) cannot be explained by a potentially suboptimal time of
sampling on days 7–10. Notably, we observed a FECR of 0% in one
school and FECRs in further three schools in the range 52–56%. In
contrast, other schools had FECRs higher than 90% or even 95%. This
variation has not been equally considered and weighted by Levecke
et al. (2018) with respect to the overall conclusion of suspected emer-
ging BZ resistance (Krücken et al., 2017). While the school showing 0%
FECR was indeed revisited on day 7 post treatment, the three schools
with 52–56% FECR were all resampled on day 10. In contrast, at the
two schools with the highest FECR of 94–95% post treatment samples
were collected on day 7. This clearly indicates that the sampling time
cannot be the main factor explaining low FECRs in our data set.
We are only beginning to understand how studies on FECR should
best be conducted and interpreted in the case of human infections. In
the veterinary field, there is plenty of data available showing that
interpretation of FECRs require host-specific modifications. Studies
such as ours and that by Levecke et al. (2018) are important to evaluate
how criteria applied in veterinary medicine should be adapted for
human infections. The logistic challenges to obtain such data are con-
siderable including the daily collection of complete faecal matter over
two weeks and the quantification of worms in these samples under field
conditions. However, such efforts will be rewarded by well-founded
criteria allowing us to answer the burning question: Is anthelimintic
resistance emerging and putting mass deworming efforts in jeopardy?
We believe that our own data (Krücken et al., 20187) and that of
Levecke et al. (2018) highlight the need and ways to progress towards
this goal, respectively.
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